Drug-Eluting Balloons

This channel includes news and new technology innovations for drug-coated balloons (DCB), also referred to as drug-eluting balloons. These are used to treat peripheral and coronary artery lesions and restenosis. The balloons carry an antiproliferative drug that is delivered to the wall of arteries when the balloon is expanded. The drug helps prevent neointimal hyperplasia (scar tissue growth) caused by trauma when the vessel segment is treated for atherosclerotic lesions with balloon angioplasty. DCBs can be used to treat hyperplasia in arteriovenous (AV) access fistulae in dialysis patients, where the vessel undergoes repeated trauma from regular punctures. DCBs also are used to treat in-stent restenosis due to scar tissue proliferation inside stents, which can cause a vessel to occlude.

News

Nov. 13, 2014 — Optimizing the treatment of coronary artery disease with a new foundation for future stent innovations ...

Home November 13, 2014
Home
Feature

Nov. 10, 2014 — For the treatment of peripheral artery disease in leg arteries above the knee, the IN.PACT Admiral drug ...

Home November 10, 2014
Home
News

October 31, 2014 — Metro Health (Michigan) cardiovascular specialist Jihad Mustapha, M.D., is one of the first ...

Home October 31, 2014
Home
News

October 29, 2014 — Restenosis, the recurrence of narrowing of the arteries after stenting, is a common risk of this ...

Home October 29, 2014
Home
News

October 14, 2014 — Presented for the first time at the 2014 Transcatheter Cardiovascular Therapeutics (TCT) conference ...

Home October 14, 2014
Home
Technology

October 13, 2014 — C. R. Bard Inc. announced the U.S. Food and Drug Administration (FDA) approval of the Lutonix 035 ...

Home October 13, 2014
Home
Feature
September 26, 2014 — A new clinical trial comparing the use of everolimus-eluting stents (EES) and drug-eluting balloons ...
Home September 26, 2014
Home
Boston Scientific Corp. CE mark Ranger Ranger Paclitaxel-coated PTA Balloon Cath
Feature

July 28, 2014 — Boston Scientific Corp. received CE mark for the Ranger Paclitaxel-coated PTA Balloon Catheter. The ...

Home July 28, 2014
Home
News
July 25, 2014 -- Continuing to advance the development of innovative treatment options for coronary artery disease ...
Home July 25, 2014
Home
FDA Recommendation Lutonix Drug Coated Balloon Catheter
Feature

June 16, 2014 — C. R. Bard Inc. announced that the U.S. Food and Drug Administration’s (FDA) Circulatory System Devices ...

Home June 16, 2014
Home
Feature

May 23, 2014 — The first drug-eluting balloon to go up for review by the U.S. Food and Drug Administration (FDA) will be ...

Home May 23, 2014
Home
News

April 16, 2014 — Patients with peripheral artery disease in the upper leg experienced significantly better outcomes at ...

Home April 16, 2014
Home
News

March 6, 2014 — Despite good immediate results, in up to 40 percent of patients, obstructed arteries in the leg treated ...

Home March 06, 2014
Home
News

March 3, 2014 — Biotronik announced the release of its Passeo-18 Lux drug-releasing balloon (DRB) in all countries ...

Home March 03, 2014
Home
News
January 30, 2014 — Experts presented six-month LEVANT 2 trial results for C. R. Bard Inc.’s Lutonix drug coated balloon ...
Home January 28, 2014
Home
Subscribe Now